Clinical Trial Update: A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating the combination therapy that includes JS212 in patients with advanced lung cancer. The study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• JS212

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Advanced Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING